Inspiratory Muscle Training in Patients With End-stage Renal Disease

Not Applicable

Completed

• Conditions: Kidney Disease

• Registration Number: NCT02599987
• Lead Sponsor: Universidade Federal de Pernambuco

Brief Summary

Background: Patients with chronic kidney disease on hemodialysis may have reduced diffusion capacity, lung function and gas exchange due to mechanical and hemodynamic changes in the respiratory system, and decreased respiratory muscle strength resulting from uremic myopathy. The inspiratory muscle training (IMT) appears as an instrument to improve the inspiratory muscle strength, with positive effects on functional capacity and quality of life of kidney patients, however, the effects of IMT were not addressed in the specific variables of the respiratory system and to date there are no studies on the use of daily training in this population. Objective: To evaluate the effectiveness of daily inspiratory muscle training on respiratory muscle strength, chest wall volume, diaphragm thickness and mobility of end-stage renal disease patients. Methods: A randomized controlled clinical trial to be developed in Cardiopulmonary Physical Therapy Laboratory of the Universidade Federal de Pernambuco (UFPE) during the period from November 2015 to December 2016. The sample is composed of 24 individuals aged 18 and 65, having CKD, to perform hemodialysis for at least twelve months and provide inspiratory muscle weakness. Patients will be divided into two groups, the training group will be IMT with POWER-breathe®, load of 50% of MIP, duration of three sets of 30 inspirations, frequency of two sessions per day, 7 days a week for 8 weeks, since the sham group will be subjected to the same procedure (duration and frequency), but without load. Participants will be assessed before and after intervention through a global assessment form, questionnaire Kidney Disease Quality of Life Instrument Short Form - KDQOL-SF, diaphragmatic ultrasound, opto-electronic plethysmography, spirometry, manometer and six-minute walk test.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-11
• Study First Submitted: 2015-11-04
• Study First Submitted QC: 2015-11-06
• Study First Posted: 2015-11-09
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-10
• Last Update Posted: 2017-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Have a chronic kidney disease
• Hemodialysis for a minimum period of twelve months
• Inspiratory muscle weakness, with MIP <80cmH2O for men and <60cmH2O for women

Exclusion Criteria

• Neurological deficit
• Chronic lung disease
• Severe heart disease (unstable angina and acute myocardial infarction)
• Decompensated diabetes
• Infectious disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Respiratory muscle strength	2 months	Evaluate by manometer
Diaphragm thickness	2 months	Evaluate by ultrasound

Secondary Outcome Measures

Name	Time	Method
Chest wall volume	2 months	Evaluate by opto-electronic plethysmography
Walking distance	2 months	Evaluate by six-minute walk test
Diaphragm mobility	2 months	Evaluate by ultrasound
Quality of life	2 months	Evaluate by questionnaire Kidney Disease Quality of Life Instrument Short Form - KDQOL-SF
Pulmonary function	2 months	Evaluate by Spirometry

Trial Locations

Locations (1)

Cardiopulmonary Physiotherapy Laboratory of UFPE; 🇧🇷 Recife, Pernambuco, Brazil